Research Paper Volume 15, Issue 23 pp 13753—13775
PBRM1 mutation and WDR72 expression as potential combinatorial biomarker for predicting the response to Nivolumab in patients with ccRCC: a tumor marker prognostic study
Figure 2. Survival analysis for patients with advanced ccRCC treated with Nivolumab and stratified by WDR72 expression and PBRM1 mutational status. (A) Kaplan-Meier curves showing OS (left panel) and PFS (right panel) in patients treated with Nivolumab divided into WDR72-High group (≥50% for OS, ≥75% for PFS) and WDR72-Low group (< 50% for OS, < 75% for PFS) in all Checkmate cohorts. (B) Kaplan-Meier curves showing OS (left panel) and PFS (right panel) in patients treated with Nivolumab divided PBRM1-WT and PBRM1-MUT in all Checkmate cohorts. (C) Kaplan-Meier curves (OS: left panel, PFS: right panel) stratified by WDR72 expression and PBRM1 mutational status for patients treated with Nivolumab in the entire cohort, according to 50rd (OS) or 75rd (PFS) percentile of WDR72 expression values. (D) Analysis of the prognostic significance of WDR72 expression and PBRM1 mutational status in patients treated with Nivolumab. Abbreviations: WDR72, WD repeat-containing protein 72; PBRM1, Recombinant Polybromo1; ccRCC, clear cell renal cell carcinoma; OS, overall survival; PFS, progression free survival; MUT, mutated; WT, wild type. HR, hazard ratio; CI, confidence interval.